Indian pharma stocks are rebounding, driven by domestic investors after a period of Foreign Institutional Investor (FII) selling pressure. Uncertainty surrounding potential US tariffs, fueled by Trump’s statements and delays in the Bilateral Trade Agreement (BTA), had initially impacted the sector. While FIIs remain cautious, positive earnings reports and the defensive nature of domestic-oriented pharma businesses are attracting DII interest.
Banks unlikely to reduce deposit rates despite RBI easing
Following the latest repo rate decrease, bankers foresee only slight adjustments to deposit rates. The landscape, characterized by sluggish savings yields and elevated credit-deposit ratios,
December 8, 2025